Date: 2016-01-12
Type of information: Private placement
Company: Epizyme (USA - MA)
Investors:
Amount: $ 130.1 million
Funding type: private placement
Planned used: Epizyme intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund the global development costs of tazemetostat, Epizyme\'s novel oral EZH2 inhibitor, outside of Japan. These costs includie the costs of the ongoing five-arm phase 2 study in patients with non-Hodgkin lymphoma; the recently initiated phase 2 study in adult patients with INI1-negative tumors, certain SMARCA4-negative tumors or synovial sarcoma; the recently initiated phase 1 study in pediatric patients with INI1-negative tumors, certain SMARCA4-negative tumors or synovial sarcoma; the planned clinical trial of tazemetostat in combination with R-CHOP in front-line elderly patients with diffuse large B-cell lymphoma; the planned clinical trial of tazemetostat in combination with a B-cell signaling agent or immuno-oncology agent in patients with B-cell non-Hodgkin lymphoma; and the planned phase 2 study of tazemetostat in BAP1-mutated mesothelioma.
The funds will also be used to initiate market development activities, begin building regulatory and commercial strategies to prepare for the global launch of tazemetostat, if approved, and expand the company\'s clinical and regulatory capabilities, fund research and development to advance the company\'s pipeline of preclinical product candidates and its programs that are subject to the Celgene collaboration and to expand its drug development platform.
Others: * On January 12, 2016, Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced the closing of its public offering of 15,333,334 shares of its common stock at a price of $9.00 per share before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 2,000,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount. The aggregate net proceeds before expenses to Epizyme from the offering are approximately $130.1 million , after deducting underwriting discounts and commissions. * On January 7, 2016, Epizyme announced the pricing of its public offering of 13,333,334 shares of its common stock at a price of $9.00 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme . In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount. * On January 5, 2016, Epizyme announced that it intends to offer and sell up to $120,000,000 of shares of its common stock in an underwritten public offering. Epizyme intends to grant the underwriters a 30-day option to purchase up to an additional $18,000,000 of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by Epizyme. Citigroup, Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-lead managers for the offering with Mizuho Securities USA Inc. acting as co-manager. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Cancer - Oncology
